Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review

The last decade has dramatically changed the strategy of anticoagulant therapy in patients with atrial fibrillation. Direct oral anticoagulants have replaced vitamin K antagonists: either direct thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According to the...

Full description

Bibliographic Details
Main Authors: B. A. Tatarsky, N. V. Kazennova
Format: Article
Language:English
Published: Столичная издательская компания 2022-11-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/2829
_version_ 1797232062131863552
author B. A. Tatarsky
N. V. Kazennova
author_facet B. A. Tatarsky
N. V. Kazennova
author_sort B. A. Tatarsky
collection DOAJ
description The last decade has dramatically changed the strategy of anticoagulant therapy in patients with atrial fibrillation. Direct oral anticoagulants have replaced vitamin K antagonists: either direct thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According to the regulatory domestic and foreign documents, the use of direct oral anticoagulants in patients with atrial fibrillation has priority in comparison with vitamin K antagonists, since they have a predictable anticoagulant effect, the possibility of taking fixed doses without the need for routine anticoagulant monitoring, rapid onset and termination of action, relatively low potential for food and drug interactions. Direct oral anticoagulants are used for the prevention of thromboembolic complications in patients with atrial fibrillation, for the prevention of deep vein thrombosis in patients who have undergone surgery on the knee or hip joints, for emergency treatment and secondary prevention of deep vein thrombosis and pulmonary embolism. Alertness to side effects tends to focus on the likelihood of bleeding, with the possibility of other side effects of direct oral anticoagulants receiving less attention or going unnoticed. These mainly include liver damage, kidney damage and a number of other rare adverse reactions. The finding of isolated thrombocytopenia in patients taking direct oral anticoagulants may be associated with a high risk of life-threatening bleeding. The article analyzes published data on the occurrence of thrombocytopenia associated with the intake of direct oral anticoagulants, and presents a clinical case of thrombocytopenia while taking apixaban.
first_indexed 2024-03-08T14:00:39Z
format Article
id doaj.art-fd379b7f6acc453ca340287afb68ff71
institution Directory Open Access Journal
issn 1819-6446
2225-3653
language English
last_indexed 2024-04-24T15:54:18Z
publishDate 2022-11-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj.art-fd379b7f6acc453ca340287afb68ff712024-04-01T07:43:43ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532022-11-0118560060510.20996/1819-6446-2022-10-062070Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature ReviewB. A. Tatarsky0N. V. Kazennova1North-West Federal Medical Research CenterNorth-West Federal Medical Research CenterThe last decade has dramatically changed the strategy of anticoagulant therapy in patients with atrial fibrillation. Direct oral anticoagulants have replaced vitamin K antagonists: either direct thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According to the regulatory domestic and foreign documents, the use of direct oral anticoagulants in patients with atrial fibrillation has priority in comparison with vitamin K antagonists, since they have a predictable anticoagulant effect, the possibility of taking fixed doses without the need for routine anticoagulant monitoring, rapid onset and termination of action, relatively low potential for food and drug interactions. Direct oral anticoagulants are used for the prevention of thromboembolic complications in patients with atrial fibrillation, for the prevention of deep vein thrombosis in patients who have undergone surgery on the knee or hip joints, for emergency treatment and secondary prevention of deep vein thrombosis and pulmonary embolism. Alertness to side effects tends to focus on the likelihood of bleeding, with the possibility of other side effects of direct oral anticoagulants receiving less attention or going unnoticed. These mainly include liver damage, kidney damage and a number of other rare adverse reactions. The finding of isolated thrombocytopenia in patients taking direct oral anticoagulants may be associated with a high risk of life-threatening bleeding. The article analyzes published data on the occurrence of thrombocytopenia associated with the intake of direct oral anticoagulants, and presents a clinical case of thrombocytopenia while taking apixaban.https://www.rpcardio.online/jour/article/view/2829drug thrombocytopeniaatrial fibrillationdabigatranrivaroxabanapixaban
spellingShingle B. A. Tatarsky
N. V. Kazennova
Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
Рациональная фармакотерапия в кардиологии
drug thrombocytopenia
atrial fibrillation
dabigatran
rivaroxaban
apixaban
title Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
title_full Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
title_fullStr Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
title_full_unstemmed Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
title_short Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
title_sort thrombocytopenia induced by direct oral anticoagulants a clinical case and literature review
topic drug thrombocytopenia
atrial fibrillation
dabigatran
rivaroxaban
apixaban
url https://www.rpcardio.online/jour/article/view/2829
work_keys_str_mv AT batatarsky thrombocytopeniainducedbydirectoralanticoagulantsaclinicalcaseandliteraturereview
AT nvkazennova thrombocytopeniainducedbydirectoralanticoagulantsaclinicalcaseandliteraturereview